190 related articles for article (PubMed ID: 26292191)
21. Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program.
Köklü S; Köksal I; Akarca US; Balkan A; Güner R; Demirezen A; Sahin M; Akhan S; Ozaras R; Idilman R
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):71-76. PubMed ID: 28051795
[TBL] [Abstract][Full Text] [Related]
22. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
[TBL] [Abstract][Full Text] [Related]
23. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
Oh JY; Kim BS; Lee CH; Song JE; Lee HJ; Park JG; Hwang JS; Chung WJ; Jang BK; Kweon YO; Tak WY; Park SY; Jang SY; Suh JI; Kwak SG
Korean J Intern Med; 2019 Jul; 34(4):794-801. PubMed ID: 29792020
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Sezaki H; Suzuki F; Hosaka T; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Liver Int; 2017 Sep; 37(9):1325-1333. PubMed ID: 28178397
[TBL] [Abstract][Full Text] [Related]
25. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Jan; 89(1):91-98. PubMed ID: 27256744
[TBL] [Abstract][Full Text] [Related]
26. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Toyoda H; Kumada T; Tada T; Takaguchi K; Ishikawa T; Tsuji K; Zeniya M; Iio E; Tanaka Y
J Gastroenterol; 2016 Jul; 51(7):741-7. PubMed ID: 26872889
[TBL] [Abstract][Full Text] [Related]
28. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Akuta N; Toyota J; Karino Y; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; McPhee F; Noviello S; Kumada H
J Gastroenterol; 2018 Sep; 53(9):1089-1097. PubMed ID: 29500489
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.
Bronowicki JP; Ratziu V; Gadano A; Thuluvath PJ; Bessone F; Martorell CT; Pol S; Terg R; Younes Z; He B; Eley T; Cohen D; Yu F; Hernandez D; McPhee F; Mendez P; Hughes E
J Hepatol; 2014 Dec; 61(6):1220-7. PubMed ID: 25038486
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
Nakamura Y; Imamura M; Kawakami Y; Teraoka Y; Daijo K; Honda F; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Chayama K
J Med Virol; 2017 Apr; 89(4):665-671. PubMed ID: 27602542
[TBL] [Abstract][Full Text] [Related]
31. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Miyazaki R; Miyagi K
Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
[TBL] [Abstract][Full Text] [Related]
32. Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
Sato A; Ishii T; Adachi K; Kumon D; Tamura T; Noguchi Y; Matsumoto N; Okuse C
Clin J Gastroenterol; 2016 Apr; 9(2):89-92. PubMed ID: 26896968
[TBL] [Abstract][Full Text] [Related]
33. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
Kan H; Hiraga N; Imamura M; Hayes CN; Uchida T; Miyaki E; Tsuge M; Abe H; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antivir Ther; 2016; 21(4):307-15. PubMed ID: 26562322
[TBL] [Abstract][Full Text] [Related]
34. Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
Zeuli JD; Adie SK; Rizza SA; Temesgen Z
Drugs Today (Barc); 2015 Nov; 51(11):629-43. PubMed ID: 26744738
[TBL] [Abstract][Full Text] [Related]
35. [Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report].
Pi SN; Chen YP
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(8):1163-4. PubMed ID: 27578593
[TBL] [Abstract][Full Text] [Related]
36. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
Kao JH; Jensen DM; Manns MP; Jacobson I; Kumada H; Toyota J; Heo J; Yoffe B; Sievert W; Bessone F; Peng CY; Roberts SK; Lee YJ; Bhore R; Mendez P; Hughes E; Noviello S
Liver Int; 2016 Jul; 36(7):954-62. PubMed ID: 26683763
[TBL] [Abstract][Full Text] [Related]
37. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Goto H; Hirooka Y
J Gastroenterol Hepatol; 2017 Nov; 32(11):1879-1886. PubMed ID: 28258705
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Cho BW; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB
Clin Mol Hepatol; 2017 Mar; 23(1):51-56. PubMed ID: 28297836
[TBL] [Abstract][Full Text] [Related]
39. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.
Uojima H; Murakami S; Nakatani S; Hidaka H; Takeuchi A; Tanaka Y; Inoue T; Yamane K; Kubota K; Nakazawa T; Shibuya A; Tanaka Y; Koizumi W
Intern Med; 2018 Apr; 57(7):951-956. PubMed ID: 29225269
[TBL] [Abstract][Full Text] [Related]
40. Daclatasvir + asunaprevir: first global approval.
Poole RM
Drugs; 2014 Sep; 74(13):1559-71. PubMed ID: 25117197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
